ESMO 2023 | IMPACT: improving therapy management with the MASCC oral agent teaching tool

Manfred K. Welslau, MD, Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany, gives an overview of findings from the IMPACT trial (NCT04030728), which compared patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching in patients with advanced breast cancer. The MOATT program resulted in reduced therapy discontinuations and enhanced patient management of oral medications such as abemaciclib. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.